Technetium (99mTc) exametazime

Technetium (^99mTc) exametazime
Clinical data
Trade names	Medi-Exametazim
License data	US FDA: Ceretec;
Routes of; administration	Intravenous
ATC code	V09AA01 (WHO) ; V09HA02 (WHO) (labelled leucocytes);
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name [[(3RS,3'RS)-3,3'-[(2,2-Dimethyltrimethylene)diimino][di-2-butanone]dioximato](3–)-N,N',N'',N''']oxotechnetium (99mTc);
CAS Number	99944-78-2 ;
PubChem CID	9552069;
UNII	3B744AG22N;
Chemical and physical data
Formula	C13H25N4O3Tc
Molar mass	383 g·mol−1
3D model (JSmol)	Interactive image; Interactive image;
Chirality	racemic
	SMILES CC1(C)CN2[Tc]3(N4C1)([N](O[H]O[N]3=C(C)[C@H]4C)=C(C)[C@H]2C)=O; ; CC1(C)CN2[Tc]3(N4C1)([N](O[H]O[N]3=C(C)[C@@H]4C)=C(C)[C@@H]2C)=O;
	(what is this?) (verify)

Technetium (^99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. Exametazime (the part without technetium) is sometimes referred to as hexamethylpropylene amine oxime or HMPAO, although correct chemical names are:

(NE)-N-[(3R)-3-[[3-[[(2R,3E)-3-hydroxyiminobutan-2-yl]amino]-2,2-dimethylpropyl]amino]butan-2-ylidene]hydroxylamine
or 3,3'-((2,2,-dimethyl-1,3-propanediyl)diimino)bis-2-butanone dioxime.